Journal of Biosciences and Medicines

Volume 10, Issue 2 (February 2022)

ISSN Print: 2327-5081   ISSN Online: 2327-509X

Google-based Impact Factor: 0.51  Citations  

Contributors to Cancer Susceptibility, Development and Treatment: Cyclic Nucleotides, Steroids and Autophagy Modulators

HTML  XML Download Download as PDF (Size: 4642KB)  PP. 65-86  
DOI: 10.4236/jbm.2022.102008    132 Downloads   498 Views  Citations

ABSTRACT

Cell autophagy and apoptosis processes are of interest in drug development and contribute to the chemotherapy outcomes of patients receiving cancer treatment. The functional roles of cyclic nucleotides in cells include maintenance of metabolic homeostasis. cGMP and steroid compounds participate in apoptotic and autophagic events, and modulate the function of multi-drug resistance proteins. Endogenous steroid and cyclic nucleotide ratios change with ageing and this may initiate detrimental changes in cell function. This study uses a computational chemistry approach to investigate molecular similarity within chemotherapeutic and steroid compound structures. Modulators of autophagy/apoptosis and endogenous steroid structures all demonstrate molecular similarity to the structure of cGMP. Relative molecular similarity within these structures facilitates additive and synergistic treatment effects. Endogenous steroids are natural modulators of autophagy and apoptosis; concentration changes consequently have the potential to impact cancer risks.

Share and Cite:

Williams, W. (2022) Contributors to Cancer Susceptibility, Development and Treatment: Cyclic Nucleotides, Steroids and Autophagy Modulators. Journal of Biosciences and Medicines, 10, 65-86. doi: 10.4236/jbm.2022.102008.

Cited by

[1] Molecular Similarity within Carcinogen and Guanine Cyclic Nucleotide Structures
Journal of Biosciences and Medicines, 2022

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.